Response: Impact of implantable cardioverter defibrillator on survival in patients with nonischemic dilated cardiomyopathy. Clin Cardiol 2023 Oct;46(10):1297-1298
Date
08/22/2023Pubmed ID
37605641Pubmed Central ID
PMC10577569DOI
10.1002/clc.24138Scopus ID
2-s2.0-85168464826 (requires institutional sign-in at Scopus site)Abstract
Our previous study aimed to investigate overall survival (OS) and sudden cardiac death (SCD) variables in nonischemic dilated cardiomyopathy (DCM) patients treated only with standard medical treatments versus those who received implantable cardioverter defibrillator (ICD) in addition to routine medical treatments. Our findings revealed no significant difference in OS between the two groups (pā=ā.25), but a significant decrease in SCD rate due to ICD insertion (pā=ā.02). Furthermore, we found no significant difference between the two groups concerning baseline characteristics and type of medical treatments received. We attempted to answer and clarify the concerning points regarding the survival benefits of ICD insertion in nonischemic DCM patients that were mentioned.
Author List
Salehi Omran H, Irilouzadian R, Hedayati Goudarzi MT, Salehi Omran MTAuthor
Hossein Salehi Omran MD Postdoctoral Researcher in the Cell Biology, Neurobiology and Anatomy department at Medical College of WisconsinMESH terms used to index this publication - Major topics in bold
Cardiomyopathy, DilatedDeath, Sudden, Cardiac
Defibrillators, Implantable
Humans
Risk Factors